Metastatic Colorectal Cancer Clinical Trial
Official title:
An Open-label, Multi-centered, Two-stage Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine in the First Line Treatment of Advanced mCRC Patients Unfit for Intense Therapy
The aim of this study is to evaluate the efficacy and safety of short course radiotherapy followed by fruquintinib combined with Sintilimab as the first-line treatment of advanced mCRC compared to bevacizumab combined with capecitabine in patients unfit for intensive therapy.
Status | Not yet recruiting |
Enrollment | 220 |
Est. completion date | January 2027 |
Est. primary completion date | January 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Have signed an informed consent; - 18 to 85 years old (including 18 and 85 years old); - Histopathologically confirmed unresectable advanced metastatic colorectal adenocarcinoma; - Have not received anti-tumor treatment for metastatic disease; - Inability to tolerate intensive treatment regimens based on oxaliplatin or irinotecan as determined by researchers; - At least one measurable lesion; - Expected life expectancy = 12 weeks; - The function of important organs within the 14 days prior to enrollment meets the following requirements (no blood components or cell growth factors are allowed to be used within the 14 days prior to enrollment): - Neutrophil absolute count = 1.5 × 10^9/L; - Platelets = 80 × 10^9/L; - Hemoglobin = 8g/dL; - Total bilirubin<1.5 times ULN; - ALT and AST<2.5 times ULN (liver metastasis patients<5 times ULN); - Serum creatinine = 1.5 times ULN; - Endogenous creatinine clearance rate>50ml/min; - International standardized ratio (INR) of coagulation function = 1.5 × ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT) = 1.5 × ULN - Women of childbearing age or men whose partners have a desire to conceive should take effective contraceptive measures. Exclusion Criteria: - Currently has a disease or condition that affects drug absorption, or the patient is unable to take oral drugs; - Currently has digestive tract diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectable tumors, or other conditions determined by the researcher that may cause gastrointestinal bleeding or perforation; - History of serious cardiovascular and cerebrovascular diseases; - Other malignant tumors within the past 5 years, excluding skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ; - Clinically uncontrolled active infection, such as acute pneumonia, active hepatitis B or hepatitis C (hepatitis B virus DNA = 1 × 104 copies/mL or>2000 IU/ml); - Currently has central nervous system (CNS) metastasis or has a history of unstable or clinically symptomatic brain metastasis; - Pregnant (positive pregnancy test before medication) or breastfeeding women; - Urine protein = 2+, or 24-hour urine protein >1.0g; - Histologically confirmed MSI-H/dMMR tumors; - Patients deemed unsuitable by the researchers for inclusion in this study. |
Country | Name | City | State |
---|---|---|---|
China | Ji Zhu | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Zhejiang Cancer Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase 1b - Objective Response Rate (ORR) | ORR according to RECIST v1.1, as assessed by the Investigator | From randomization until disease progression (up to approximately 3-5 years) | |
Primary | Phase 2 - Progression-free Survival (PFS) | PFS according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by the Investigator | From randomization until disease progression (up to approximately 3-5 years) | |
Secondary | Tolerability and safety of study regimens | Number of Participants With Treatment-emergent Adverse Events (TEAEs) according to CTCAE v5.0 | From randomization until the end of treatment (up to approximately 3-5 years) | |
Secondary | Disease Control Rate (DCR) | DCR according to RECIST v1.1, as assessed by the Investigator | From randomization until disease progression (up to approximately 3-5 years) | |
Secondary | Overall Survival OS) | OS according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by the Investigator | From randomization until disease progression (up to approximately 3-5 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01228734 -
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
|
Phase 3 | |
Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
Completed |
NCT01591421 -
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05412706 -
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
|
Phase 2 | |
Withdrawn |
NCT04430985 -
FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Withdrawn |
NCT03182894 -
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05725200 -
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Terminated |
NCT03176264 -
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
|
Phase 1 | |
Completed |
NCT04866290 -
HepaSphere™ Microspheres Prospective Registry
|
||
Not yet recruiting |
NCT06425133 -
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
|
Phase 2 | |
Not yet recruiting |
NCT05531045 -
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
|
||
Withdrawn |
NCT03982173 -
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
|
Phase 2 | |
Completed |
NCT02906059 -
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02575378 -
Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer
|
Phase 4 | |
Withdrawn |
NCT02535988 -
Abscopal Effect for Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT02848807 -
Chemotherapy-related Toxicity, Nutritional Status and Quality of Life
|
N/A | |
Active, not recruiting |
NCT02077868 -
Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
|
Phase 3 | |
Completed |
NCT02414009 -
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT01949194 -
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
|
Phase 2 | |
Withdrawn |
NCT01915472 -
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
|
Phase 2 |